You can buy or sell TRIL and other stocks, options, and ETFs commission-free!
Trillium Therapeutics Inc. Common Shares, also called Trillium Therapeutics, is a clinical stage immuno-oncology company, which engages in the research and development of therapies for the treatment of cancer. Its pipeline is comprised of TTI-621, TTI-622, and TTI-10001 (Sting Agonist). The company was founded on March 31, 2004 and is headquartered in Mississauga, Canada. The listed name for TRIL is Trillium Therapeutics Inc. Common Shares.
52 Week High
52 Week Low
— per share
-$0.55 per share